Explore more price target data and ratings for NeoGenomics, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for NeoGenomics, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This informatio…
Oncology (cancer) diagnostics company NeoGenomics NASDAQ:NEO reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on year to $201.7 million. The company expects the full year’s revenue to be around $804 million, close to analysts’ estimates. Its non-GAAP profi…
NeoGenomics reported second-quarter 2026 consolidated revenue of $201.7 million, an 11% increase year-over-year, driven by clinical services revenue growth. The company recorded GAAP net income of $2.2 million and delivered adjusted EBITDA of $14.5 million, up 36% versus the prior-year quarter. Neo…
Q2 2026 saw 11% revenue growth and 36% higher adjusted EBITDA, with gross margin expanding 260bps. Guidance for 2026 was raised, reflecting strong clinical and NGS performance, margin expansion, and robust cash flow. Debt maturity was extended and infrastructure investments advanced.Original docume…
NEOGENOMICS INC reported results for the period ended 2026 with revenue of $201.66M, net income of $2.24M and diluted EPS of $0.02, versus $181.33M, a net loss of ($45.09M) and diluted EPS of ($0.35) in the prior-year period.Financial Highlights¹ Reported as “Net Revenue”. ² Reported as “Net Income…
Q2 2026 revenue grew 11% year-over-year to $202 million, with clinical services up 14% and NGS revenue up 26%. Adjusted EBITDA rose 36% to $14 million, and full-year guidance was raised for both revenue and EBITDA. Net income reached $2 million, reversing a prior-year loss.Original document: NeoGen…
NEO (NeoGenomics, Inc.) is set to announce its Q2'26 results on July 28, after the market closes. The earnings are expected to be disclosed at 4:00 PM ET (8:00 PM UTC).For Q2'26, revenue estimate is 196.92 million USD with EPS (earnings per share) anticipated at 0.03 USD. Learn more details at NEO…
NEO (NeoGenomics, Inc.) is set to announce its Q2'26 results on July 28, after the market closes. The earnings are expected to be disclosed at 4:00 PM ET (8:00 PM UTC).For Q2'26, revenue estimate is 196.92 million USD with EPS (earnings per share) anticipated at 0.03 USD. Learn more details at NEO…
Explore more price target data and ratings for NeoGenomics, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for NeoGenomics, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This informatio…
FORT MYERS, Fla.--(BUSINESS WIRE)--July 07, 2026--NeoGenomics, Inc. NASDAQ:NEO, a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, Jul…
